[6-K] Evaxion A/S Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Evaxion A/S filed a Form 6-K furnishing a press release dated October 8, 2025 that announces the company has expanded its AI-Immunology™ platform by adding an automated vaccine design module. The filing states the press release is provided as Exhibit 99.1 and that this Form 6-K is incorporated by reference into several of the company's registration statements, to the extent not superseded by later filings. No financial metrics, commercialization milestones, timeline, or technical performance data for the new module are included in the filing.

Positive

• AI-Immunology™ platform expanded with an automated vaccine design module
• Press release formally furnished as Exhibit 99.1, ensuring disclosure to investors
• Filing incorporated by reference into multiple registration statements, preserving disclosure linkage

Negative

• No financial or timeline data for the new module is provided in the filing
• No validation, clinical, or commercialization details are disclosed to demonstrate near-term impact
• Press release text not included here; the filing only furnishes the release as an exhibit

Insights

Biotech Product Strategist

Platform update: an engineering step that could streamline vaccine design workflows.

The company reported an expansion of its AI-Immunology™ platform with an automated vaccine design module, which is an operational enhancement rather than a disclosed commercial agreement or financial event. The announcement signals a technology development focus but the filing provides no metrics, validation data, or partner commitments tied to the module.

This development depends on subsequent demonstration of technical performance, regulatory acceptability, and potential integration into existing programs; the filing does not provide dates or milestones. Investors can note the capability expansion, but material commercial or clinical impact is not shown in the disclosed text.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On October 8, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion expands AI-Immunology™ platform with automated vaccine design module". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion expands AI-Immunology™ platform with automated vaccine design module

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: October 8, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion (EVAX) announce on October 8, 2025?

The company announced it expanded its AI-Immunology™ platform by adding an automated vaccine design module, as furnished in Exhibit 99.1.

Is there financial or commercial impact disclosed for EVAX from the platform expansion?

No. The Form 6-K does not disclose any financial metrics, revenues, contracts, or commercialization terms related to the module.

Where can investors find the full press release for EVAX's platform update?

The press release is furnished as Exhibit 99.1 to the Form 6-K; investors should review Exhibit 99.1 for the full text.

Does the filing state any timelines or milestones for the new automated vaccine design module?

No. The filing does not include dates, schedules, validation milestones, or regulatory steps for the module.

Was the Form 6-K incorporated by reference into other Evaxion registration statements?

Yes. The filing states it is incorporated by reference into several registration statements, including forms S-8 and F-3/F-1 filings listed in the document.